Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intercalating Gefitinib and Chemotherapy in Resected EGFR-mutant NSCLC
NCT03381066Phase 3Unknown
- Sponsor
- Yonsei University
- Start
- Apr 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gefitinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yonsei University. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03381066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381066.